Massachusetts Society of Clinical Oncologists - Three New ASCO Guidelines Published

"The Voice of Oncology in Massachusetts"

Back to list

Three New ASCO Guidelines Published

March 28, 2024 3:10 PM | Katy Monaco (Administrator)

On March 13, the Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline was published. Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use. Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial. Cannabis and/or cannabinoids may improve refractory, chemotherapy induced nausea and vomiting when added to guideline-concordant antiemetic regimens. Several tools, including a recommendations table, slides, clinician and patient focused podcasts, a patient summary, and a pocketcard, which is free to ASCO members, accompany the guideline.
On March 18, the Vaccination of Adults with Cancer: ASCO Guideline was published. Optimizing vaccination status should be considered a key element in the care of patients with cancer. This approach includes the documentation of vaccination status at the time of the first patient visit; timely provision of recommended vaccines; and appropriate revaccination after hematopoietic stem-cell transplantation, chimeric antigen receptor T-cell therapy, or B-cell–depleting therapy. A recommendations table, slides, podcast, patient summary, fact sheet, and a pocketcard, which is free for ASCO members, are available.
On March 19, the Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update was published. The guideline provides recommendations for first-line, second-line, and third-line systemic therapy. An algorithm, recommendations table, slides, patient information, podcast, and a pocketcard, which is free to ASCO members, are available

ADDRESS

860 Winter Street, Waltham, MA, 02451

tel: 781.434.7329

msco@mms.org

Join Our Mailing List